By partnering with DNAnexus, 37 MDA Care Centers can analyze data from the MOVR Data Hub to better understand disease progression and compare results across therapeutic categories
New York, October 28, 2020 – The Muscular Dystrophy Association (MDA) today announced the launch of the Visualization and Reporting Platform (VRP) for Neuromuscular Observational Research (MOVR). The new platform represents a monumental leap in advancing neuromuscular disease research and improving patient care. MDA has partnered with DNAnexus, the leading cloud-based SaaS company serving the life science community, to unleash the power of its MOVR Data Hub and develop the MOVR VRP to drive drug discovery and development.
MDA has redoubled its efforts to ensure that those who have a direct impact on the lives of people with neuromuscular disease have cutting-edge tools to share data and accelerate research and treatment progress. We are grateful to the MOVR participants who agreed to make their data available for this purpose, and employees of the MDA Care Center who have worked tirelessly to populate MOVR. The MOVR database combined with the DNAnexus visualization and analysis platform enables us to use this data in such a way that it really comes to life to help in the development of new therapeutics.
Lynn O’Connor Vos, President & CEO of MDA.
MDA has partnered with DNAnexus to transform raw MOVR data and incorporate it into MOVR-VRP, where clinicians and researchers at the MDA Care Center can analyze and visualize data across multiple Care Center locations to better understand disease progression understand and compare results across therapeutic categories.
The platform’s security, compliance, and collaboration components will increasingly make MOVR data accessible to the broader neuromuscular clinical and research community. Targeted efforts include training, meeting data requirements, reviewing publications, promoting peer-to-peer collaboration and publishing, and sharing insights across multiple channels to raise awareness. MOVR data now complies with data protection and HIPAA regulations and the FDA-mandated format for observational clinical studies.
From my experience with the MOVR VRP, I can say that the user interface is very intuitive and customizable. Once operational, this innovative platform will be an invaluable tool for clinicians and researchers at the MDA Care Center across the country to visualize the aggregated data from all locations and help enormously in our therapeutic decisions and the structuring of clinical trials.
Jeffrey M. Statland, MD, Assistant Professor of Neurology and Director of the MDA Care Center at the University of Kansas Medical Center, who beta tested the new platform
The MOVR VRP not only helps improve clinical care, but also enables in-depth analysis of clinical parameters in large cohorts of neuromuscular patients. This will enable correlative analyzes that can stimulate new drug, biologic and gene therapy discoveries. Examining these deeply curated cohorts of neuromuscular disorders in the MOVR-VRP also enables clinical researchers to quickly identify populations that meet certain clinical criteria, develop and refine hypotheses, and collaborate on clinical trial designs.
Extracting value from the data first requires a comprehensive strategy for harmonizing and ingesting data. DNAnexus has a successful track record of collecting valuable records from the UK Biobank, City of Hope and now MOVR, and works with a variety of popular data models such as OMOP, CDISC and other data schemes to support each customer’s unique use case The Importance of Collaboration for scientific advancement and the development of new approaches to revolutionize research on neuromuscular diseases. We pride ourselves on serving as a technology platform where MDA researchers and their partners come together to advance the healing of this collection of neuromuscular diseases.
Richard Daly, CEO at DNAnexus.
Read press release